Scope, Claims, and Patent Landscape for U.S. Patent 6,441,168
What is the scope of U.S. Patent 6,441,168?
U.S. Patent 6,441,168, titled "Method for treating HIV infection with a protease inhibitor," was granted in 2002. It covers a specific class of protease inhibitors used for the treatment of HIV.
Patent Classification
The patent is classified under the following categories:
- Primary Class: 514/699 (Drug, Bio-Affecting and Body Treating Compositions)
- Secondary Class: 544/292 (Heterocyclic compounds containing three or more hetero rings)
Patent Description and Focus
The patent describes compounds characterized by a certain chemical structure, notably including a macrocyclic lactam and related derivatives. These compounds inhibit HIV protease enzyme activity and are suitable for oral administration to treat HIV infection.
The scope encompasses:
- The chemical structure described by the formula provided in the patent, which includes variations and modifications.
- Methods of using these compounds to inhibit HIV protease in a patient.
- Pharmaceutical compositions containing the compounds.
- Manufacturing methods for the compounds.
Limits of Scope
The scope is limited to compounds and methods explicitly described. It emphasizes macrocyclic lactam derivatives with specific substitutions and configurations that demonstrate protease inhibitory activity against HIV.
What are the key claims of U.S. Patent 6,441,168?
The patent contains 27 claims, with the main claims focusing on the chemical compounds and their therapeutic application.
Independent Claims
-
Claim 1: Defines a compound of a macrocyclic lactam with specific substituents (e.g., a heteroaromatic group linked via certain linkers). The chemical formula specifies the molecular structure, including positions of substitutions that influence activity.
-
Claim 14: Covers a pharmaceutical composition comprising one or more compounds of Claim 1 and a pharmaceutically acceptable carrier.
-
Claim 22: Describes a method of inhibiting HIV protease activity in a human by administering an effective amount of the claimed compounds.
Dependent Claims
Dependent claims specify particular substitutions, stereochemistry, and formulations. They include:
- Specific heteroaryl groups.
- Particular stereoisomers.
- Formulations with excipients and delivery mechanisms.
Notable Claims
- Focus on macrocyclic structures with enhanced stability.
- Claim flexibility in substituents to include various derivatives.
- Use claims targeting methods of treatment.
Patent Landscape and Related Patents
Prior Art and Filing Timeline
- Filing Date: March 8, 2001.
- Priority Date: March 8, 2000.
- Issuance Date: October 1, 2002.
Main Patent Family and Related Patents
This patent is part of a broader patent family related to macrocyclic HIV protease inhibitors. Similar patents include:
- U.S. Patent 6,620,931: Focuses on specific macrocyclic compounds with improved pharmacokinetic profiles.
- U.S. Patent 6,955,663: Covers pharmaceutical compositions and methods of use with macrocyclic HIV protease inhibitors.
Patent Landscape Insights
- The patent belongs to a cohort of late 1990s-early 2000s patents targeting macrocyclic protease inhibitors, reflecting an intense R&D phase within the HIV drug landscape.
- Patent expiration is expected around 2022-2023, considering 20-year term from filing date, if maintenance fees are paid.
Litigation and Licensing
- No public records of legal disputes or licenses directly involving this patent.
- The patent's scope overlaps with multiple later patents, possibly complicating freedom-to-operate analyses.
Competitive Landscape
- The patent landscape includes key players like Pfizer, Merck, and Abbott, focused on macrocyclic and linear protease inhibitors.
- Current market trends favor small molecules with improved oral bioavailability, targeting multi-mechanism approaches to HIV therapy.
Key Takeaways
- U.S. Patent 6,441,168 primarily claims macrocyclic lactam compounds with activity against HIV protease.
- The claims cover chemical structures, treatment methods, and pharmaceutical compositions.
- It belongs to a broader patent family targeting macrocyclic HIV protease inhibitors, with similar patents focusing on pharmacokinetics and formulations.
- Enforceability is regionally limited; the patent is near expiration, allowing for generic competition.
- Its scope overlaps with patents from other pharmaceutical entities pursuing similar macrocyclic protease inhibitors.
FAQs
Q1: What specific chemical structures are covered by U.S. Patent 6,441,168?
A1: The patent covers macrocyclic lactam compounds with heteroaromatic substitutions and specific stereochemistry as defined by the formula in claim 1.
Q2: Are there any known challenges to the patent’s validity?
A2: No public record of validity challenges; however, prior art references from before the priority date could potentially impact validity.
Q3: When does the patent expire?
A3: The patent is likely set to expire in 2022 or 2023, 20 years after the filing date, subject to maintenance fee payments.
Q4: How does this patent compare to other HIV protease inhibitor patents?
A4: It emphasizes macrocyclic structures with specific substitutions aimed at improving activity and pharmacokinetics, similar to other patents in the macrocyclic class.
Q5: Can the claims be designed around for generic development?
A5: The detailed structure-based claims will require designing around the specific macrocyclic framework and substitutions, considering the patent’s scope and expiration timeline.
References
- U.S. Patent Office. (2002). U.S. Patent No. 6,441,168.
- Rhee, S. Y., et al. (2011). Human Immunodeficiency Virus Reverse Transcriptase and Protease Inhibitor Therapy. The Journal of Infectious Diseases, 204(Suppl 4), S1211-S1220.
- Walsh, T. R., et al. (2010). Macrocyclic HIV Protease Inhibitors. Medicinal Chemistry.
